# Jade Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Jade Biosciences, Inc.). ## Overview Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for autoimmune diseases. Its pipeline centers on monoclonal antibodies designed to improve dosing convenience, maintain a comparable safety profile, and potentially deliver stronger clinical activity than existing approaches. ## Products & services • JADE101 anti-APRIL monoclonal antibody for IgA nephropathy • JADE201 anti-BAFF-R monoclonal antibody for autoimmune diseases • JADE301 monoclonal antibody against an undisclosed target • Preclinical discovery and in-licensing of biologic drug candidates • Clinical development services for internally owned pipeline assets - **Lead clinical programs** (70%) — JADE101 and JADE201 are the company’s main clinical-stage antibody programs targeting autoimmune disease pathways. - **Preclinical pipeline** (20%) — JADE301 and other discovery-stage assets represent earlier-stage programs intended to expand the pipeline. - **Business development and licensing** (10%) — The company seeks to in-license or option third-party biologic candidates and related intellectual property. - JADE101: anti-APRIL mAb initially for IgA nephropathy - JADE201: anti-BAFF-R mAb for multiple autoimmune disorders - JADE301: undisclosed-target mAb in preclinical development - In-licensing and option-based acquisition of biologic programs - Preclinical, clinical, and translational development of antibody assets ## Customers Jade Biosciences does not yet sell approved products, so its near-term “customers” are primarily regulators, clinical trial participants, and development partners rather than commercial buyers. If its programs succeed, the eventual end customers would be physicians, hospitals, and patients in autoimmune disease markets such as IgA nephropathy and rheumatoid arthritis. The company’s value proposition is aimed at treatment settings where improved dosing, convenience, and clinical activity can differentiate a biologic from existing therapies. - **Clinical trial participants** (primary) — Patients enrolled in Phase 1 and future studies who generate safety, PK, and proof-of-concept data. - **Autoimmune disease prescribers** (primary) — Nephrologists, rheumatologists, and other specialists who would prescribe approved products if development succeeds. - **Pharmaceutical partners** (secondary) — Potential licensing or collaboration partners that may fund development or commercialize assets. - **Regulatory agencies** (primary) — FDA and foreign regulators that determine whether programs can advance into and through clinical development. - Patients with autoimmune diseases enrolled in clinical trials - Physicians and specialists treating IgA nephropathy and RA - Regulators reviewing INDs and clinical data packages - Potential pharma partners for licensing or commercialization - Research collaborators and CRO/CMO service providers ## Geography Jade Biosciences is headquartered in the United States and operates as a U.S.-based development-stage biotech company. The filings disclose a Phase 1 JADE101 trial in New Zealand, showing that clinical execution is already international even though the company has no product revenue and no disclosed geographic sales mix. Its geography is therefore driven more by trial sites, CRO/CMO relationships, and regulatory pathways than by commercial market presence. - Headquartered in the United States - Clinical trial activity includes New Zealand for JADE101 - No product revenue or country sales disclosure to date - Operations depend on third-party CROs and CMOs across locations - Future commercialization would likely expand beyond the U.S. ## Strategy The company’s strategy is to build a differentiated autoimmune-disease pipeline around biologics that can show better dosing convenience and competitive pharmacology. Near term, it is prioritizing JADE101 clinical execution, while JADE201 and JADE301 broaden the platform and create optionality for future indications and partnerships. - **Advance JADE101 clinical development** (short-term) — The company says it is substantially dependent on JADE101 and is investing most resources there. - **Build JADE201 into a multi-indication autoimmune asset** (medium-term) — A broader indication set could create a larger commercial opportunity if early data are positive. - **Expand pipeline through JADE301 and external in-licensing** (medium-term) — Additional assets reduce single-program dependence and increase the chance of finding a differentiated candidate. - Advance JADE101 through early clinical development - Use JADE201 to build a broader autoimmune franchise - Develop JADE301 as a third pipeline option - Pursue in-licensing of external biologic assets - Target best-in-class profiles with rapid proof-of-concept ## Risks Jade Biosciences is a preclinical/clinical-stage biotech with no approved products, so its business depends on successful trial outcomes, regulatory approvals, and access to capital. The company also relies heavily on third-party CROs, CMOs, and collaborators, which creates execution, quality, and supply-chain risk in addition to the usual drug-development and competitive risks. - **Clinical development failure for JADE101** [critical] — The company states it is substantially dependent on JADE101 and expects success to depend on IgA suppression and improved PK in humans. - **Capital access and dilution risk** [high] — The company expects substantial additional funding needs before product revenue and may need equity or other financing. - **Third-party development and manufacturing dependence** [high] — Research, trials, and manufacturing are largely outsourced to CROs, CMOs, and collaborators. - **Regulatory and trial-timing risk** [high] — Delays or negative regulatory outcomes can shorten exclusivity and allow competitors to reach market first. - **Cybersecurity and data integrity risk** [medium] — Clinical and vendor data systems are exposed to breaches, outages, and unauthorized access. - No approved products means no commercial revenue yet - JADE101 trial failure would materially weaken the pipeline - Clinical delays can reduce exclusivity and competitive position - Heavy reliance on CROs, CMOs, and Paragon increases execution risk - Future funding needs could force dilution or program delays ## Accounting As a development-stage biotech, Jade Biosciences’ reported results are driven mainly by research and development accruals, stock-based compensation, and fair-value accounting for investments and financing-related items. Because it has no product revenue, investors should focus on how third-party study and manufacturing costs are accrued, how stock compensation affects operating losses, and whether cash runway assumptions remain consistent with ongoing trial spending. - **Research and development accruals** — Affects operating loss timing and comparability - **Stock-based compensation** — Affects reported R&D and G&A costs - **Investment and cash runway disclosures** — Affects liquidity analysis and financing expectations - R&D costs are accrued as incurred for CRO and CMO work - Third-party study and manufacturing estimates affect quarterly expense timing - Stock-based compensation is a meaningful operating expense - No product revenue yet, so losses reflect development spend - Cash and investment balances drive going-concern and runway analysis --- *Last updated: 2026-04-28T20:18:54.965794+00:00*